PRZOOM - /newswire/ -
Winston-Salem, NC, United States, 2009/11/05 - SmallCapReview.com, a leading small-cap stock information site, is pleased to announce that Sanmina-SCI Corporation (Nasdaq: SANM) and Micrus Endovascular Corp. (Nasdaq: MEND) have been added to its Portfolio.
Sanmina-SCI (SANM) is a leading electronics contract manufacturer serving the fastest-growing segments of the global Electronics Manufacturing Services (EMS) market. Recognized as a technology leader, Sanmina-SCI provides end-to-end manufacturing solutions, delivering superior quality and support to OEMs primarily in the communications, defense and aerospace, industrial and medical instrumentation, multimedia, enterprise computing and storage, renewable energy and automotive technology sectors. Sanmina-SCI has facilities strategically located in key regions throughout the world.
SANM Investor Highlights
SANM has world-class manufacturing facilities in 18 countries and four continents.
Sanmina-SCI's Defense and Aerospace Systems (DAS) division leverages more than 40 years of experience and is the world's number one provider of defense and aerospace electronics design and manufacturing services.
Revenue for Q$ '09 of $1.35 billion, exceeded outlook of $1.2 - $1.3 billion.
Revenue for the fourth quarter was $1.35 billion, up 12 percent, compared to $1.21 billion in the prior quarter.
Cash balance of $899.2 million.
Recently announced that its Huntsville, Alabama facility has been awarded the National Aerospace and Defense Contract Accreditation Program (NADCAP) accreditation.
Micrus Endovascular (MEND) develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and endovascularly trained neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke.
Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The Micrus product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrus’ proprietary, three-dimensional microcoils anatomically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes.
Micrus also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires and accessory products used in conjunction with its microcoils.
The company has operations in the Americas, Europe, and the Asia Pacific.
MEND Investor Highlights
Net income for the second quarter of fiscal 2010 was $3.6 million, or $0.22 per diluted share.
Total revenues increased increased to 9% (or 12% in constant currencies) to $42.7 million in the first six months.
Neurovascular revenues from the U.S. increased 15% to a record $11.2 million in the second quarter, and increased 16% to $21.3 million in the first six months.
Revenues from Europe increased 5% (or 8% in constant currencies) to $6.4 million in the second quarter, and increased 9% (or 18% in constant currencies) to $12.7 million in the first six months.
Announced along with Flexible Stenting Solutions Inc.., the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indications using both Micrus and Flexible Stenting Solutions technology, development capabilities and intellectual property. Unlike microcoils that are placed in the aneurysm, flow diverters are stent-like devices placed in the parent vessel. They serve to divert blood flow away from the aneurysm, thus facilitating healing.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
SmallCapReview.com is not a registered investment advisor or broker/dealer. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. SmallCapReview has not been compensated by any of the above mentioned companies nor do we hold any positions at this time. SmallCapReview may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report.